CHMP of EMA conveyed negative trend vote of Puma’s MA for neratinib for treating HER2-positive…
Puma Biotechnology asserted that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has conveyed a negative trend vote after discussions…
Read More...
Read More...
